• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非转移性肾细胞癌的随访管理:监测方案的定义

The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol.

作者信息

Antonelli Alessandro, Cozzoli Alberto, Zani Danilo, Zanotelli Tiziano, Nicolai Maria, Cunico Sergio Cosciani, Simeone Claudio

机构信息

Department of Urology, University of Brescia, Brescia, Italy.

出版信息

BJU Int. 2007 Feb;99(2):296-300. doi: 10.1111/j.1464-410x.2006.06616.x.

DOI:10.1111/j.1464-410x.2006.06616.x
PMID:17326263
Abstract

OBJECTIVE

To define a follow-up protocol based on the University of California Los Angeles Integrated Staging System (UISS) for patients undergoing surgery for N0M0 renal cell carcinoma (RCC).

PATIENTS AND METHODS

The clinical records of patients treated with radical surgery for N0/NXM0 RCC and monitored through periodic follow-up studies (> or =24 months in disease-free patients) were reviewed retrospectively from 1399 patients surgically treated for renal neoplasms between 1983 and 2005. Each case was assigned a UISS risk category; recurrence features, time and site were recorded. In particular, recurrence sites were categorized into local, renal (ipsilateral or contralateral) and distant (single-site or disseminated).

RESULTS

The records were reviewed of 814 patients with a mean follow-up of 75.6 months. UISS risk categories were distributed as follows: high-risk (HR) 17.2%, intermediate-risk (IR) 51.6% and low-risk (LR) 31.2%. Disease-free survival rates at 5 years were 63.9%, 88.3% and 96.5% (log-rank test P < 0.001), respectively. The disease recurred in 193 patients (23.7%), at distant sites (73.0% of recurrences), locally (11.9%), in the contralateral kidney (10.9%) and in the ipsilateral kidney (4.1%). There was a significant correlation between UISS category and risk of distant or local (both P < 0.001) recurrences, whereas there was no correlation of recurrences in the operated kidney (P = 0.372) or contralateral kidney (P = 0.898).

CONCLUSIONS

The prognostic accuracy and applicability of the UISS for distant and local recurrences is confirmed, whereas renal relapses have an independent course. A follow-up scheme tailored to the recurrence patterns observed in each UISS risk group is recommended.

摘要

目的

为接受手术治疗的N0M0肾细胞癌(RCC)患者制定基于加利福尼亚大学洛杉矶分校综合分期系统(UISS)的随访方案。

患者与方法

回顾性分析1983年至2005年间1399例接受肾肿瘤手术治疗患者的临床记录,这些患者接受了N0/NXM0 RCC根治性手术,并通过定期随访研究进行监测(无病患者随访时间≥24个月)。为每个病例指定一个UISS风险类别;记录复发特征、时间和部位。特别是,复发部位分为局部、肾脏(同侧或对侧)和远处(单部位或播散性)。

结果

对814例患者的记录进行了回顾,平均随访时间为75.6个月。UISS风险类别分布如下:高危(HR)17.2%,中危(IR)51.6%,低危(LR)31.2%。5年无病生存率分别为63.9%、88.3%和96.5%(对数秩检验P<0.001)。193例患者(23.7%)出现疾病复发,复发部位为远处(占复发的73.0%)、局部(11.9%)、对侧肾脏(10.9%)和同侧肾脏(4.1%)。UISS类别与远处或局部复发风险之间存在显著相关性(两者P<0.001),而手术侧肾脏(P = 0.372)或对侧肾脏(P = 0.898)的复发无相关性。

结论

UISS对远处和局部复发的预后准确性和适用性得到证实,而肾脏复发有独立的病程。建议根据每个UISS风险组观察到的复发模式制定随访方案。

相似文献

1
The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol.非转移性肾细胞癌的随访管理:监测方案的定义
BJU Int. 2007 Feb;99(2):296-300. doi: 10.1111/j.1464-410x.2006.06616.x.
2
Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system.基于经过验证的预后列线图和风险组分层系统的局限性和局部进展性肾细胞癌患者术后监测方案
J Urol. 2005 Aug;174(2):466-72; discussion 472; quiz 801. doi: 10.1097/01.ju.0000165572.38887.da.
3
Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.肾切除术后非转移性肾细胞癌四种预后模型预测准确性的比较:一项欧洲多中心研究
Cancer. 2005 Oct 1;104(7):1362-71. doi: 10.1002/cncr.21331.
4
Integrated staging systems for conventional renal cell carcinoma: a comparison of two prognostic models.传统肾细胞癌的综合分期系统:两种预后模型的比较
Arch Ital Urol Androl. 2011 Sep;83(3):121-7.
5
Use of the University of California Los Angeles Integrated Staging System (UISS) to predict survival in localized renal cell carcinoma in an Asian population.
Int Urol Nephrol. 2007;39(3):699-703. doi: 10.1007/s11255-006-9134-1. Epub 2006 Dec 19.
6
Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system.保留肾单位手术治疗肾细胞癌的疗效:基于1997年新的肿瘤-淋巴结-转移分期系统的分析。
J Clin Oncol. 1999 Sep;17(9):2868-75. doi: 10.1200/JCO.1999.17.9.2868.
7
Renal cell carcinoma: The role of radical surgery on different patterns of local or distant recurrence.肾细胞癌:根治性手术对局部或远处复发不同模式的作用。
Surg Oncol. 2020 Dec;35:106-113. doi: 10.1016/j.suronc.2020.08.002. Epub 2020 Aug 13.
8
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study.使用加利福尼亚大学洛杉矶分校综合分期系统预测肾细胞癌的生存率:一项国际多中心研究。
J Clin Oncol. 2004 Aug 15;22(16):3316-22. doi: 10.1200/JCO.2004.09.104.
9
Impact of routine imaging in the diagnosis of recurrence for patients with localized and locally advanced renal tumor treated with nephrectomy.根治性肾切除术治疗局限性和局部进展性肾肿瘤患者的常规影像学检查对复发诊断的影响。
World J Urol. 2019 Dec;37(12):2727-2736. doi: 10.1007/s00345-019-02724-8. Epub 2019 Mar 20.
10
Positive surgical margin following radical nephrectomy is an independent predictor of local recurrence and disease-specific survival.根治性肾切除术后的阳性切缘是局部复发和疾病特异性生存的独立预测因子。
World J Surg Oncol. 2017 Nov 2;15(1):193. doi: 10.1186/s12957-017-1257-6.

引用本文的文献

1
SEC14L3 knockdown inhibited clear cell renal cell carcinoma proliferation, metastasis and sunitinib resistance through an SEC14L3/RPS3/NFκB positive feedback loop.SEC14L3 knockdown 抑制透明细胞肾细胞癌的增殖、转移和舒尼替尼耐药,通过 SEC14L3/RPS3/NFκB 正反馈回路。
J Exp Clin Cancer Res. 2024 Oct 19;43(1):288. doi: 10.1186/s13046-024-03206-5.
2
Minimally invasive nephron-sparing treatments for T1 renal cell cancer in patients over 75 years: a comparison of outcomes after robot-assisted partial nephrectomy and percutaneous ablation.75 岁以上患者 T1 期肾细胞癌的微创保肾治疗:机器人辅助部分肾切除术与经皮消融术治疗效果比较。
Eur Radiol. 2023 Dec;33(12):8426-8435. doi: 10.1007/s00330-023-09975-5. Epub 2023 Jul 19.
3
CEACAM1 Is a Prognostic Biomarker and Correlated with Immune Cell Infiltration in Clear Cell Renal Cell Carcinoma.CEACAM1 是透明细胞肾细胞癌的预后生物标志物,并与免疫细胞浸润相关。
Dis Markers. 2023 Jan 18;2023:3606362. doi: 10.1155/2023/3606362. eCollection 2023.
4
Can Pre-Operative Neutrophil-to-Lymphocyte Ratio (NLR) Help Predict Non-Metastatic Renal Carcinoma Recurrence after Nephrectomy? (UroCCR-61 Study).术前中性粒细胞与淋巴细胞比值(NLR)能否帮助预测肾切除术后非转移性肾癌的复发?(UroCCR - 61研究)
Cancers (Basel). 2022 Nov 19;14(22):5692. doi: 10.3390/cancers14225692.
5
HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma.HMGCR 抑制作用稳定糖酵解酶 PKM2 以支持肾细胞癌的生长。
PLoS Biol. 2021 Apr 27;19(4):e3001197. doi: 10.1371/journal.pbio.3001197. eCollection 2021 Apr.
6
Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.透明细胞肾细胞癌免疫细胞浸润景观,以辅助免疫治疗。
Cancer Sci. 2021 Jun;112(6):2126-2139. doi: 10.1111/cas.14887. Epub 2021 Apr 7.
7
Liquid Biopsies in Renal Cell Carcinoma-Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease.肾细胞癌中的液体活检——转移性疾病早期检测的最新进展和有前景的新技术
Front Oncol. 2020 Oct 28;10:582843. doi: 10.3389/fonc.2020.582843. eCollection 2020.
8
Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant.RAB27B 通过外泌体非依赖功能在包括舒尼替尼耐药的肾细胞癌中的致癌作用。
PLoS One. 2020 May 7;15(5):e0232545. doi: 10.1371/journal.pone.0232545. eCollection 2020.
9
Reassessment of American Joint Committee on Cancer Staging for Stage III Renal Cell Carcinoma With Nodal Involvement: Propensity Score Matched Analyses of a Large Population-Based Study.美国癌症联合委员会对伴有淋巴结转移的Ⅲ期肾细胞癌分期的重新评估:一项基于大人群研究的倾向评分匹配分析
Front Oncol. 2020 Mar 19;10:365. doi: 10.3389/fonc.2020.00365. eCollection 2020.
10
Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?靶向转录因子受体 LXR 治疗透明细胞肾细胞癌:激动剂还是反向激动剂?
Cell Death Dis. 2019 May 28;10(6):416. doi: 10.1038/s41419-019-1654-6.